You just read:

Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRα D842V Mutation

News provided by

Blueprint Medicines Corporation

Jun 05, 2017, 08:00 ET